Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. 2013

David C Weksberg, and Pamela K Allen, and Karen E Hoffman, and Jennifer K Litton, and Eric A Strom, and Ruchita R Shah, and Henry M Kuerer, and Kelly K Hunt, and Thomas A Buchholz, and Elizabeth A Mittendorf
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

BACKGROUND There are few data addressing local-regional recurrence (LRR) and salvage therapies in patients treated with neoadjuvant chemotherapy (NCT) compared to those treated with surgery first. We characterize the clinical course and predictive features of salvage treatment for LRR after breast conserving therapy (BCT) analyzed by initial treatment. METHODS We identified 1,589 patients who underwent BCT; 1,141 (72 %) patients underwent initial surgery, and 448 (28 %) received NCT. Kaplan-Meier and Cox regression analyses were performed to analyze factors associated with overall survival (OS), local control (LC) of recurrence, and distant metastasis-free survival (DMFS) following LRR. RESULTS 56 patients had a LRR, for a crude recurrence rate of 3 %. For patients with potentially curable recurrence (excluding distant metastases within 3 months of LRR), the 5-year OS, LC, and DMFS rates were 52, 77, and 69 %. On multivariate analysis, initial pathologically negative node status and use of surgery for salvage were significant factors associated with higher OS. Additionally, older age was associated with higher LC rates after salvage. Estrogen receptor-positive disease and surgery for LRR were associated with reduced risk of distant metastases; regional recurrence and use of initial adjuvant chemotherapy were associated with increased risk of distant metastases. For each of these endpoints, the addition of NCT to the multivariate model did not approach significance. CONCLUSIONS LRR is an uncommon event after BCT and many patients with LRR remain curable (5-year OS >50 %). Our data indicate that NCT does not compromise salvage after LRR, providing further assurance that this strategy is safe for appropriately selected breast cancer patients.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002285 Carcinoma, Intraductal, Noninfiltrating A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma. Carcinoma, Intraductal,DCIS,Ductal Carcinoma In Situ,Atypical Ductal Hyperplasia,Intraductal Carcinoma, Noninfiltrating,Atypical Ductal Hyperplasias,Carcinoma, Noninfiltrating Intraductal,Carcinomas, Intraductal,Carcinomas, Noninfiltrating Intraductal,Ductal Hyperplasia, Atypical,Ductal Hyperplasias, Atypical,Hyperplasia, Atypical Ductal,Hyperplasias, Atypical Ductal,Intraductal Carcinoma,Intraductal Carcinomas,Intraductal Carcinomas, Noninfiltrating,Noninfiltrating Intraductal Carcinoma,Noninfiltrating Intraductal Carcinomas
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females

Related Publications

David C Weksberg, and Pamela K Allen, and Karen E Hoffman, and Jennifer K Litton, and Eric A Strom, and Ruchita R Shah, and Henry M Kuerer, and Kelly K Hunt, and Thomas A Buchholz, and Elizabeth A Mittendorf
March 1992, Surgery, gynecology & obstetrics,
David C Weksberg, and Pamela K Allen, and Karen E Hoffman, and Jennifer K Litton, and Eric A Strom, and Ruchita R Shah, and Henry M Kuerer, and Kelly K Hunt, and Thomas A Buchholz, and Elizabeth A Mittendorf
March 2012, Annals of surgical oncology,
David C Weksberg, and Pamela K Allen, and Karen E Hoffman, and Jennifer K Litton, and Eric A Strom, and Ruchita R Shah, and Henry M Kuerer, and Kelly K Hunt, and Thomas A Buchholz, and Elizabeth A Mittendorf
June 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
David C Weksberg, and Pamela K Allen, and Karen E Hoffman, and Jennifer K Litton, and Eric A Strom, and Ruchita R Shah, and Henry M Kuerer, and Kelly K Hunt, and Thomas A Buchholz, and Elizabeth A Mittendorf
October 2016, Breast care (Basel, Switzerland),
David C Weksberg, and Pamela K Allen, and Karen E Hoffman, and Jennifer K Litton, and Eric A Strom, and Ruchita R Shah, and Henry M Kuerer, and Kelly K Hunt, and Thomas A Buchholz, and Elizabeth A Mittendorf
November 2005, International journal of radiation oncology, biology, physics,
David C Weksberg, and Pamela K Allen, and Karen E Hoffman, and Jennifer K Litton, and Eric A Strom, and Ruchita R Shah, and Henry M Kuerer, and Kelly K Hunt, and Thomas A Buchholz, and Elizabeth A Mittendorf
March 1993, Cancer,
David C Weksberg, and Pamela K Allen, and Karen E Hoffman, and Jennifer K Litton, and Eric A Strom, and Ruchita R Shah, and Henry M Kuerer, and Kelly K Hunt, and Thomas A Buchholz, and Elizabeth A Mittendorf
October 1993, Cancer,
David C Weksberg, and Pamela K Allen, and Karen E Hoffman, and Jennifer K Litton, and Eric A Strom, and Ruchita R Shah, and Henry M Kuerer, and Kelly K Hunt, and Thomas A Buchholz, and Elizabeth A Mittendorf
December 1989, Nederlands tijdschrift voor geneeskunde,
David C Weksberg, and Pamela K Allen, and Karen E Hoffman, and Jennifer K Litton, and Eric A Strom, and Ruchita R Shah, and Henry M Kuerer, and Kelly K Hunt, and Thomas A Buchholz, and Elizabeth A Mittendorf
September 2003, The British journal of surgery,
David C Weksberg, and Pamela K Allen, and Karen E Hoffman, and Jennifer K Litton, and Eric A Strom, and Ruchita R Shah, and Henry M Kuerer, and Kelly K Hunt, and Thomas A Buchholz, and Elizabeth A Mittendorf
March 1988, Annals of surgery,
Copied contents to your clipboard!